Latest news with #TTR
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Vedanta contributed ₹4.5 trn to govt in last 10 yrs, ₹55,349 cr in FY25
Anil Agarwal-led Vedanta Ltd has contributed Rs 4.5 lakh crore to the government exchequer over the last 10 years. In its annual Tax Transparency Report (TTR), the company reaffirmed its commitment to transparent and responsible tax practices. The company said it has "contributed Rs 4,48,830 crore to exchequer across its domestic and international operations over the past decade (FY15-16 to FY24-25)." In FY25 alone, the company contributed Rs 55,349 crore (37 per cent of the consolidated revenue) through direct and indirect taxes, royalties, dividends, and other statutory payments. Of this, Rs 54,595 crore was contributed to the exchequer. In India, Vedanta has operations in 15 states, with Rajasthan operations contributing Rs 25,436 crore and Odisha Rs 9,176 crore to the exchequer in FY25. Vedanta Ltd, a subsidiary of Vedanta Resources, is one of the world's leading natural resources, critical minerals, energy and technology companies, spanning across India, South Africa, Namibia, Liberia, UAE, among others.
Scoop
5 days ago
- Politics
- Scoop
Tribunal Asked To Halt Seabed Mine Fast-Track
South Taranaki hapū want the Waitangi Tribunal to halt a fast-track bid to mine the seabed off Pātea. Trans-Tasman Resources (TTR) has applied under the new Fast-track Approvals Act to mine in the South Taranaki Bight for 20 years. The mining and processing ship would churn through 50 million tonnes of the seabed annually, discharging most of it back into the ocean in shallow water just outside the 12-nautical-mile territorial limit. Hapū and iwi are seeking a tribunal injunction to block processing of TTR's fast-track application. The claimants want an urgent hearing into alleged Crown breaches and are seeking to summon Crown officials they say are responsible. They say the Crown failed to consult tangata whenua, breaching Te Tiriti o Waitangi and ignored a Supreme Court ruling against the seabed mine. To get an urgent Waitangi Tribunal hearing, applicants must be suffering or likely to suffer significant and irreversible prejudice, as a result of current or pending Crown actions. Lead claimant Puawai Hudson of Ngāruahine hapū Ngāti Tū said their moana was rich in taonga species. "If seabed mining goes ahead, we lose more than biodiversity - we lose the mauri that binds us as Taranaki Mā Tongatonga [people of south Taranaki]," Hudson said. The area was also subject to applications under the Marine and Coastal Area Act - the law that replaced the Foreshore and Seabed Act. "This is not consultation - this is colonisation through fast-track." The applicants' legal team, who're also of Ngāruahine, say the Wai 3475 claim breaks new ground. Legal tautoko Alison Anitawaru Cole and Te Wehi Wright said the Court of Appeal proved the tribunal's powers to require Crown action in urgent and prejudicial cases, when it summonsed Children's Minister Karen Chhour. They argue the tribunal should be able to halt other urgent and prejudicial Crown actions - such as processing TTR's application under the Fast-track Approval Act (FAA). The Taranaki claimants are: all hapū of Ngāruahine iwi their school Te Kura o Ngā Ruahine Rangi Te Rūnanga o Ngāti Ruanui Ruanui hapū including Ngāti Tupaea Parihaka Papakainga Trust Groups outside Taranaki facing FAA applications have also joined, including Te Rūnanga o Ngāti Porou ki Hauraki. As opponents press their claim, TTR is due to argue its case this week at New Plymouth District Council (NPDC). Trans-Taman said opposition to seabed mining lacked scientific credibility and the waste sediment it discharges would be insignificant, given the load already carried by the turbid Tasman Sea. TTR managing director Alan Eggers is expected to lay out his wares to councillors at a public workshop on Wednesday morning. The company promises an economic boost in Taranaki and Whanganui, creating more than 1350 New Zealand jobs and becoming one of the country's top exporters. The only known local shareholder - millionaire Phillip Brown - last week was reported to lodge a complaint to NPDC, alleging bias by its iwi committee, Te Huinga Taumatua. The Taranaki Daily News reported Brown thought tribal representatives and councillors on the committee talked for too long during a deputation opposed to TTR's mining bid. After the hour-and-a-quarter discussion, Te Huinga Taumatua co-chair Gordon Brown noted it was a record extension of the officially allotted 15 minutes. The committee, including Mayor Neil Holdom, voted that the full council should consider declaring opposition to TTR's mine, when it meets on 24 June. Brown reportedly believed the meeting was procedurally flawed and predetermined. Iwi liaison committees in north and south Taranaki typically relax debate rules to allow fuller kōrero. Taranaki Regional Council's powerful policy and planning committee recently reached a rare accord on dealing with freshwater pollution, when its new chair - Māori constituency councillor Bonita Bigham - suspended standing orders in favour of flowing discussion. Ngāti Ruanui has stood against Trans-Tasman for more than a decade, including defeating their application in the Supreme Court. Rūnanga kaiwhakahaere Rachel Arnott said the Crown should know mana whenua would never give up. "We are still here, because our ancestors never gave up fighting for what is right.
NZ Herald
5 days ago
- Business
- NZ Herald
Waitangi Tribunal asked to halt Pātea seabed mine fast-track
South Taranaki hapū want the Waitangi Tribunal to halt a fast-track bid to mine the seabed off Pātea. Trans-Tasman Resources (TTR) has applied under the new Fast-track Approvals Act to mine in the South Taranaki Bight for 20 years. The mining and processing ship would churn through 50 million tonnes
Yahoo
13-06-2025
- Business
- Yahoo
The European Commission Approves Alnylam's AMVUTTRA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM). A researcher studying genetic medicines under a microscope in a biopharmaceutical laboratory. As a result, AMVUTTRA is the first and only RNAi treatment approved in the EU for transthyretin amyloidosis symptoms that show as cardiomyopathy and polyneuropathy. The HELIOS-B Phase 3 research, which revealed a 36% mortality reduction over 42 months and a 28% decrease in all-cause mortality and recurrent cardiovascular events, served as the basis for the approval. More than 6,000 patient-years of safety data support the quarterly administration of the medication. The drug is already authorized in Brazil and the United States. Up to 100,000 individuals in Europe have ATTR amyloidosis, mostly as cardiomyopathy. An RNAi treatment called vutrisiran provides continuous knockdown by stopping TTR production at its source with quarterly injections. Functional and quality-of-life gains were validated by the HELIOS-B trial, which involved patients on SGLT2 inhibitors and tafamidis. Elevations of liver enzymes and injection site responses are frequent adverse effects. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is an innovator in the investigation of RNA interference medicines. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C. Wainwright, raised the price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) from $53 to $56 and kept the stock's buy rating. A team of scientists in white lab coats reviewing lab results in a research facility. Positive momentum for the company is proven by the fast uptake of the Attruby product, which is the driving force behind this bullish forecast. For adult patients with ATTR-CM, Attruby is the only nearly full (≥90%) stabilizer of Transthyretin (TTR) that has been approved in the United States to lower cardiovascular mortality and hospitalizations linked to cardiovascular disease. In general, Attruby was highly received. Abdominal pain and diarrhea were the most frequent, moderate side effects that went away without stopping the medication. BridgeBio Pharma, Inc. (NASDAQ:BBIO) provides a wide range of initiatives to facilitate patients' access to our medications. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a novel biopharmaceutical business that was established to find, develop, test, and distribute revolutionary medications to treat people with hereditary disorders. The development programs in its pipeline span from early science to advanced clinical trials. BBIO is among the stocks with the biggest upside. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
